Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.

View Full Paper
Ask AI
Bookmark
Share

Authors

LBLihua E. BuddeCity Of Hope National Medical CenterTDTheresa DeisherAVM Biotechnology (United States)DSDon A. StevensTufts Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Budde et al. (2024) studied this question.

synapsesocial.com/papers/68e66db4b6db6435875f86a5https://doi.org/10.1200/jco.2024.42.16_suppl.7077
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL.2024
  2. 2Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.2024 · 1 citations
  3. 3MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)2025 · 1 citations
  4. 4Abstract CT173: Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma2024 · 1 citations
  5. 5Abstract CT032: ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study2026